AC Immune (ACIU) Research & Development (2015 - 2026)

AC Immune (ACIU) has reported Research & Development for 12 consecutive years, with -$15.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development rose 15.28% year-over-year to -$15.0 million; the TTM figure through Mar 2026 stood at -$65.0 million (up 9.01% YoY), while the FY2025 annual figure was -$68.1 million, up 4.7% from the prior year.
• Research & Development slipped to -$15.0 million in Q1 2026 per ACIU's latest filing, from -$13.3 million in the prior quarter.
• Across five years, Research & Development topped out at -$13.3 million in Q4 2025 and bottomed at -$20.3 million in Q2 2025.
• Historically, Research & Development has averaged -$16.3 million across 5 years, with a median of -$16.3 million in 2025.
• Annual changes were most pronounced in 2022 — Research & Development climbed 28.01% — and 2024, when it decreased 24.54%.
• AC Immune's Research & Development stood at -$15.7 million in 2022, then retreated by 5.08% to -$16.5 million in 2023, then fell by 9.15% to -$18.0 million in 2024, then gained by 26.24% to -$13.3 million in 2025, then declined by 12.84% to -$15.0 million in 2026.
• Business Quant data shows ACIU's Research & Development at -$15.0 million in Q1 2026, -$13.3 million in Q4 2025, and -$16.3 million in Q3 2025.